Try our Advanced Search for more refined results
Life Sciences - January, 2023
319 articles
- DEA Faulted Controls At Opioid Distributors, Ga. Jury Hears
- DC Circ. Revives FOIA Suit Seeking Execution Drug Info
- Amgen, Horizon Say FTC Is Reviewing Proposed $28B Merger
- Achaogen Claims Over Lost Ch. 11 Sales Can Go Forward
- CBD Co. Beats Some Claims By Ex-Stratton Oakmont Trader
- Nonprofit Takes French Fry Cancer Case To High Court
- J&J's Case Axed, But Door Not Shut On 'Texas 2-Step' Ch. 11s
- Riding Circuit: February's Notable Oral Arguments
- Meta Cites Privacy In COVID Misinformation Subpoena Fight
- Calif. Pot Regulators Ask State AG About Interstate Pot Trade
- Consumers Raise Stink About Diaper Genie's 1-Yr. Supply Ads
- What 2023 Has In Store For The Cannabis Industry
- ImmunoGen Loses Trial Bid To Secure Cancer Therapy Patent
- AngioDynamics Fights For New Trial In CR Bard Patent Case
- Lessons From Fed. Circ. Ruling On Lung Disease Patent
- Biotech Goosed Stock With Omicron Vax Claims, Suit Says
- Cipla Files Fresh Bid To Revoke Bayer's Xarelto Patent
- Opioid Victim Families Go To Trial Against Distributors In Ga.
- Feds Call Convicted Theranos COO Balwani A 'Flight Risk'
- White House To End COVID-19 Emergency Declarations In May
- Bernstein Litowitz Nabs $7.7M Fees In Stericycle Case
- Ex-Outcome Health Execs' Greed Led To $1B Fraud, Jury Told
- Canadian Pharma Co.'s Units File $61M Ch. 15 In Delaware
- New ACA Birth Control Exemptions Cover Faith, Not Morality
- Walgreens To Pay $7M In FCA Suit Over Hepatitis C Drugs
- Cooley-Led Biotech Firm Launches Plans For $125M IPO
- PTAB Rules Against Apple In Masimo Blood Oximetry IP Fight
- HHS Can't Force 'Unlimited' Drug Discounts, 3rd Circ. Says
- Investors Say Biopharma Execs Hid New Migraine Drug Issues
- Trending At The PTAB: Evidence For Priority Cases
- Mich. Doctor Gets 16 Years For $100M Opioid Pill Scheme
- Cannabis Cos. Must Brace For More Mislabeling Class Actions
- Mass. Launches Abortion Hotline Staffed By BigLaw, ACLU
- NY Hospital's Vax Firing Violated Bias Laws, Worker Says
- 3rd Circ. Throws Out J&J Talc Unit's 'Texas Two-Step' Ch. 11
- Pharma Co. Hit With 2nd Suit Over $1.8B AstraZeneca Deal
- Sen. Warren Wants FTC Scrutiny Of $29B Pharma Deals
- Benefits Co. Can't Escape J&J's Suit Over Patient Drug Fund
- Generic Zantac Makers Want Final Judgment In Fla. MDL
- Pharma Co. Appeals Malpractice Loss Against Polsinelli
- 5 Ways Attorneys Can Use Emotion In Client Pitches
- UK Litigation Roundup: Here's What You Missed In London
- Pharma Whistleblower Asks 2nd Circ. To Revive Kickback Suit
- California Exec Convicted Of $157M Drug Scheme
- Taylor Wessing Pursues 'Strategic Alliance' With Madrid Firm
- 2 Firms Lead Finnish Pharma Biz €12M Share Fundraising
- Investors Say Cannabis REIT Should Have Known About Ponzi
- IP Forecast: Intel To Spar With ParkerVision In Patent Trial
- 6th Circ. Vexed By Ex-Smuckers Workers' COVID-19 Vax Suit
- Ariz. Tribe Sues McKinsey Over Opioid Crisis
- Judge Won't Silence J&J's $3B Damages Estimate In IP Suit
- RFK Jr.-Repped Doc Wins Halt Of COVID Misinformation Law
- PTAB Upholds Testing Patents After Ravgen's $272M Jury Win
- Zantac Suits Consolidated In NY After Fla. MDL Tossed
- Tricida Gets OK To Seek Stalking Horse For Ch. 11 Auction
- GlaxoSmithKline Biased Against Older Workers, Chemist Says
- Drug Co. Ends Product Endorsement Fight With Ga. Professor
- Teva Can't Get HHS Docs For Kickback Defense
- In Blow To Hemp Industry, FDA Punts On CBD Rules
- AstraZeneca Sales Reps See Pay Bias Suit Axed, For Now
- Europe's New Unitary Patent System Will Affect IP Agreements
- Nichols Liu Adds Career Corporate Ethics Officer To DC Group
- SPAC Buys Longevity In $236.2M Deal Led By 2 Firms
- 5 Keys To A Productive Mediation
- Pfizer Bid To Shield FBI Talks Meets Skeptical Judge
- DC Circ. Questions FDA Appeal Process In E-Cig Case
- Jury To Decide If Allergan Sale Included Arbitration Clause
- Bristol-Myers Gets Pushback On Early Win Bid Over Cancer IP
- Regeneron Gets Novartis Syringe Patent Axed At PTAB
- Shareholders Sue Sotera After $363M Emissions Verdict
- Abortion Drug Restrictions Draw Challenges In W.Va., NC
- Gopuff Hits COVID-19 Test Supplier With $1.1M Contract Suit
- Tech Co. Drops Suit Over Wire Fraud Coverage
- Juul MDL Paused As 9th Circ. Reviews Class Certifications
- Horse Trainer Gets 5 Years In Doping Scheme
- Rare COVID Benefits Award Yields Workers' Comp Road Map
- Gilead Wants US To Face Defenses Before HIV Patent Trial
- Pension Fund Urges 11th Circ. To Revive Suit Against MiMedx
- New Clinical Trial Law Promotes Diversity And Modernization
- Investor Files Securities Suit Over $952M Albireo Merger
- Ex-Olympic Skater Pleads Guilty To COVID Relief Fraud
- 4th Circ. Weighs Help Of W.Va. Justices In Pelvic Mesh Appeal
- Purdue Warns Tribe's NY Lawsuit Could 'Blow Up' Ch. 11 Plan
- DOD, Ex-Sergeants Spar Over Dismissal Of Vax Mandate Row
- Procter & Gamble Duped DayQuil, Vitamin C Buyers, Suit Says
- Reed Smith Opens Orange County Office, Firm's 5th In Calif.
- Conducting M&A Transactions In A Challenging Market
- 1st Circ. Reels Aetna Back Into Knee Implant Libel Suit
- Kroger Seeks Insurance Coverage For Over 700 Opioid Suits
- Holmes Says Feds' Claims Of Mexico Escape Plans Are False
- Pharma Co. Faces Investor Suit Over $1.8B AstraZeneca Deal
- Novartis Tells Justices Judge Swap Wrongly Sunk Patent Win
- 11th Circ. Backs Fla. Man's Medicare Fraud Conviction
- Court Consolidates Takeda Antitrust Suits Over IBS Drug
- Bard Vascular Filter Case In Georgia Settles On Eve Of Trial
- High Court Won't Take On SEIU Union Dues Deduction Suit
- Judge Put On 'Blinders' In Merck Patent Fight, Fed. Circ. Told
- Evaluating The Legal Ethics Of A ChatGPT-Authored Motion
- After Catalyst Case, FDA Won't Stop Approving Orphan Drugs
- Developments To Watch In Trade Secret Practice This Year
- Velsicol Must Face Suit Over Pesticide Made By Predecessor
- Real Estate Rumors: Cointreau, Vanbarton, Sunshine Sachs
- Catching Up With Delaware's Chancery Court
- Former Troutman Pepper Attys Launch Goodwin Philly Office
- Juul's $255M Economic Loss MDL Deal To Get Green Light
- Attys For Takeda Employees Want $7.3M On 401(k) Lineup Suit
- J&J Unit Says Rival Is Still Flooding Market Despite Verdict
- Daiichi Slams Seagen's Bid To Nix Cancer Drug Patent Award
- FTC Wants Shkreli Held In Contempt Over Stonewalling
- Flint, Groups Set New Water Pipe Replacement Deadline
- A Look At The Legal Intersection Of AI And Life Sciences
- MoCRA: 6 Key Takeaways From The New Cosmetics Law
- AndroGel Patent Suit Ruled Baseless For Antitrust Claims
- Focus On Drug's Cancer-Killing Potential, Judge Tells Biotech
- Lessons On Prior Art From PTAB's Genetic Testing Decisions
- HHS Vows Audits, Publicity Targeting Nursing Home Practices
- Pharmacy Owner Convicted Of Paying $25M In Kickbacks
- Ex-CytoDyn CEO Sues In Del. Chancery Court For Legal Fees
- Defense Wants 'Rule-Breaking' Plaintiffs' Attys Off Wage Case
- Feds Say Elizabeth Holmes' Flight Risk 'Never Been Higher'
- NJ Judge Signs Off On $1.3M Atty Fee In Immunomedics Suit
- 7 Tips To Increase Your Law Firm's DEI Efforts In 2023
- Cancer Patient Files Civil Rights Suit Against Attys, Monsanto
- Keys To A 9-0 High Court Win: Get Back To Home Base
- High Court Legacy Of FCA Unity Teeters On Ideological Brink
- Exelixis Notches Win Against MSN In Cancer Drug Patent Trial
- IP Forecast: Pfizer Wants Talks With FBI Kept Under Wraps
- PPE Fraud Suit Ends In $2.1M Judgment For Fla. Reseller
- Juul Investor Seeks Limited Scope In April Vaping Trial
- J&J Unit Takes Aim At Doctors Linking Talc To Mesothelioma
- Indian Drug Distributor Gets 7 Years For Trafficking Pills In US
- Incorrect Inventorship On Patents Is A Tough Claim To Prove
- Ex-SPAC Founder Fights For Legal Fees Over Merger Probe
- Goodwin Adds Former Chief Counsel Of Health Agency's OIG
- Endo Gets Approval For Fee Deal With State Governments
- Justices Seek Feds' Input In Ex-Shkreli Atty's 401(k) Fight
- Supreme Court Says It Hasn't Identified Dobbs Leaker
- 5th Circ. Upholds Lincare's Win In Ex-Worker's Race Bias Suit
- EU Medicine Reboxing Ruling Gives Guidance To Pharma Cos.
- The 7th Circ.'s Top 10 Civil Opinions Of 2022
- Section 230 Saves Retailers From Model's Likeness Suit
- Walmart Aims To 'Weaken' Opioid Script Laws, DOJ Says
- Investors, Inovio Get Final OK For $44M Deal In Stock Suit
- 3 Firms Lead Biotech Deal With Wilbur Ross-Backed SPAC
- Becton Dickinson Investor Seeks Cert. In Pump Recall Suit
- Olly Can't Duck Claims Over Too Much Melatonin In Products
- Atty-Client Privilege Arguments Give Justices A Moving Target
- Jazz Pharma Unit Sues Over Cannabis Seizure Drug Patent
- W.Va. AG Inks $83M Opioid Deal With Walgreens
- Justices Ignite FCA Debate: Fairness Vs. 'Invitation To Fraud'
- FDA Urges Texas Judge Not To Reverse Abortion Pill Approval
- Fed. Circ. Urged Not To Reverse Jazz's Orange Book Delisting
- Calif. Wants High Court To Toss $302M J&J Mesh Fine Appeal
- Mich. County Loses Challenge To $800M Opioid Payout Plan
- 5 Gen X Characteristics That Can Boost Legal Leadership
- Pharma Co. Seeks $2M Fee For Bid In Canceled Ch. 11 Auction
- 10th Circ. Skeptical Of Forcing Arbitration In ESOP Row
- Catching Up With Delaware's Chancery Court
- Mallinckrodt Ruling Holds Creditor Lessons For IP Sellers
- Pfizer Asks Appeals Court To Limit Damages In Lyrica Suit
- Alabama Water District Joins PFAS MDL Against 3M, Others
- Endo Claimants Say It's Time For Alternative Ch. 11 Plans
- Pharmacies And Drug Cos. Want Out Of Texas Opioid MDL
- Attorneys See Sober Outlook For Deals After JP Morgan Event
- Life Sci Partners Tapped For Withers Boston Office
- What To Expect From Justices' FCA Scienter Standard Review
- Voyager Sells Digital Assets For $1B, FTX Finds $5B In Crypto
- 6th Circ. Slams Door On Wholesaler's Opioid Coverage Fight
- Fla. Jury Says J&J Unit Is Owed $59.5M In Implant Patent Fight
- New Ill. Law Aims To Protect Out-Of-State Abortion Patients
- Law360 Names Practice Groups Of The Year
- Predictions For The 2023 Drug Pricing Landscape
- Bausch Hits Aurobindo With Gastro Drug Patent Suit
- 6 Questions For Boutique Firms Considering Mergers
- Time To Revisit A Little-Used Patent Tool
- Rubber Co. Fights Bid To Toss Hidden Labor Violation Suit
- 3M Wants Early Win Against Distributor In N95 Trademark Suit
- Supreme Court Will Scrutinize FCA's Scienter Standard
- 3 Legal Ethics Issues For Psychedelics Attorneys
- 10th Circ. To Mull Forced Arbitration Of ERISA Class Actions
- Biotech Co. Tricida Gets Bankruptcy Auction Fast-Tracked
- MRI Co., Receptionist Reach Deal To End Discrimination Suit
- Dow Chemical Wants Out Of Tech Firm's Trade Secrets Spat
- 'I've Had My Fill,' Ill. Judge Says In Express Scripts Suit
- Calif. Says Insulin Makers, PBMs Overcharge Diabetics
- Fed. Circ. Stuck On How To Appeal PTAB Policy In Fintiv Case
- Ex-Takeda Employee, Boyfriend Charged With $2.3M Fraud
- 3rd Circ. Presses US On Mylan's $50M Tax Bill For Court Costs
- Testing The Doctrine of Equivalents' Chemical Patent Context
- Paramedical Services Co. Settles TCPA Suit Over Robocalls
- Bain Capital Invests $400M In Biorefinery Co. EcoCeres
- Ex-NFL Player Drops 2 Defendants From Suit Over PPE Deal
- Biotech Tricida Hits Ch. 11 In Del. With $350M Debt, Sale Plans
- Acorda Says It's Owed $65M More In MS Drug Fight
- Duane Morris Boosts Silicon Valley Office With IP, Trial Pros
- Astellas Sues Chinese Rival To Block Generic Bladder Drug
- Walgreens Overcharges For Kids' Cough Medicine, Suit Claims
- Azurity Can't Duck Bionpharma's Sham Suit Claims
- Latest Illumina-Grail Appeal Challenges EU Separation Order
- 6 Takeaways From LabSolutions 'Unnecessary Testing' Verdict
- Ohio Pharma Board Must Reconsider Dispensary Application
- Mo. High Court Vacates $5M Geico Payout In HPV Suit
- Judge Pushes Resolution In Vanda, FDA Gastro Drug Fight
- Fennec Sues Cipla Over Generic Hearing Loss Treatment Bid
- The Issues Shaping Labor Market Antitrust Litigation In 2023
- Colo. Agency Calls For More Rules On Kratom Makers
- ITC Judge Rules That Apple Watch Infringes Masimo Patent
- Philips Stops Chinese Rivals From Using Stolen Trade Secrets
- 6th Circuit Won't Put Brakes On Ky. Securities Fraud Probe
- Tulane, Insurers Finalize Settlement Of COVID Coverage Suit
- FDA Drug Approvals Don't Include Impurities, DC Circ. Rules
- Pending Appeal, Balwani Asks To Stay Out Of Prison
- Bayer Sunscreen Settlement Nets Class Attys $766K
- Choctaw Nation Asks 9th Circ. To Reverse Arbitration Order
- Exploring The Amgen Genus Claims Headed To High Court
- Real Estate Rumors: Feil, Teva Pharmaceuticals, Somerset
- Chancery Class Seeks Rare AmerisourceBergen Ruling Redo
- Pa. Records Office Must Review Health Dept. Pot Recall Docs
- BioNTech To Buy Rest Of UK AI Startup Through $439M Deal
- Juul Founders Must Face NY AG's Underage Marketing Suit
- Midterm Cannabis Results Remind That Progress Is Not Linear
- Cipriani & Werner Sues Aurobindo Pharma For $3.8M MDL Tab
- Ex-Aegerion Rep In Talks With Feds To Avoid 2nd Fraud Trial
- 5 Tips For Adding Value To Legal Clients' Experience In 2023
- USPTO Strategic Plan Met With Praise, Calls For More Details
- 1st Circ. Backs GSK's Preemption Win Against Zofran MDL
- Resonetics To Buy Medical Materials Biz In Deal Worth $900M
- Bionpharma Can't Get Drug Patent Suit Tossed
- Novartis Gets OK On $126M Deal To End Drug Delay Claims
- Endo Ch. 11 Could Stiff Future Opioid Claimants, Judge Told
- Sterigenics To Pay $408M To End Over 870 Emissions Suits
- Arthrex Returns To High Court With Hirshfeld Challenge
- Justices Deny Juno Rehearing Bid After Amgen Cert. Grant
- 4 Key Issues Driving Drug Discount Abuse Must Be Addressed
- IQVIA Thwarts Research Co.'s Early Exit From Poaching Suit
- Lewis Brisbois, Weil Guide $335M Cancer Biotech SPAC Deal
- Justices Jilt Pfizer's Kickback Attack, But Dispute Isn't Done
- Fed. Circ. Patent Decisions In 2022: An Empirical Review
- Catching Up With Delaware's Chancery Court
- Lathrop GPM Adds Veteran Patent Prosecutor In Chicago
- Bayer's Ex-Top Lawyer Joins Software Giant SAP As GC
- Teva Says $4.3B Global Opioid Deal Can Move Ahead
- Bayer Whistleblower Attys Want $2.2M In Fees For FCA Suit
- Pharma Biz Sues PE Firm In Delaware, Alleging Raid On Staff
- 3 Firms Lead French Pharma Biz's $952M Biotech Co. Deal
- Greenberg Traurig Nabs Biotech IP Atty From Kasowitz
- Idaho, SC Top Courts Diverge On Abortion Access
- Linklaters' Partner Firm Adds Disputes Partner In Beijing
- FDA Clears New Alzheimer's Drug Amid Lingering Controversy
- Investor Sues To Halt $615M Boston Scientific Deal
- Amolyt Pharma Closes $138M Series C Round Of Financing
- Green Groups Fight Another Bid To Delay Fluoride Risks Case
- Fed. Circ. Says Thermo Fisher Can't Beat Interference Loss
- Cannabis Co. Can't Toss Investors' Stock Drop Suit
- 5 Major Drug And Device Developments Of 2022
- 11th Circ. Again Denies Shire's Bid To Dodge Label Case
- Health Hires: Kymera Therapeutics, Crown Laboratories
- UK Litigation Roundup: Here's What You Missed In London
- The Hottest FCA Cases & Trends To Watch In 2023
- Amgen Doesn't Want Chemistry Group's Help At High Court
- Lantus Buyers Line Up As Plaintiffs In Recast Class Action
- Altria Accuses Juul Of Hiding Vaping Settlement Details
- CBD Drug Co. Alleges Teva, Others Violated Patents
- 11th Circ. Axes Docs' Pill Convictions After High Court Ruling
- Investor Says Biotech Co. Hid Blood Treatment Funding Woes
- Bill Aims To Stomp Out Doping In NY Horse-Racing Industry
- Zimmer Buys Medical Tech Co. Embody For Up To $275M
- Horizon Therapeutics Investor Sues To Halt $28B Amgen Deal
- GenapSys Ch. 11 Plan Confirmed After $42M Asset Sale
- California Water District Joins 'Forever Chemicals' MDL
- Cahill Gordon Lands King & Spalding Patent Litigator
- 6th Circ. Orders Probe Of When Lilly Burglar Heard About Deal
- Goodwin Nabs Investment, Real Estate Partner In New York
- Invisalign Maker Says SmileDirect 'Built On A Lie' In New Suit
- Dinsmore Picks Up Ex-Middleton Reutlinger IP Pros
- Bills To Decriminalize Psychedelics Filed In 4 States
- Calbiotech Can't Avoid ERISA Suit Over Safe Harbor 401(k)
- 3rd Circ. Preview: NCAA Athlete Pay Fight Tops Jan. Calendar
- Key Takeaways From 2022 Trade Secret Developments
- Express Scripts Antitrust Suit Is 'Off The Rails,' Judge Says
- Abbott Wins $26M Against Retailer In Test Strips TM Row
- Priest, Hedge Fund Founder Can't Ax SEC's Win In Fraud Suit
- In Holmes' Sentencing, Judge Has Warning For All Companies
- Preparing For Congressional Oversight Of Chinese Trade
- FDA's 1st Cannabis Adviser May Mean CBD Regulation In 2023
- Enviro Group Sues FEMA For Info On Fossil Fuel Spending
- FDA Paves Way For Pharmacy Chains To Offer Abortion Pills
- Health & Pharma Legal Clashes Didn't Take A Holiday Break
- Tenn. And Wash. Join FTC's Generic Pesticide Blocking Suit
- Amgen Gets Broad Support In High Court Patent Fight
- Calif. Panel Sides With Restaurant After COVID-19 Settlement
- Fed. Circ. Won't Bar Generic Sleep Meds Amid Vanda Appeal
- Catching Up With Delaware's Chancery Court
- Potential Upheaval For FDA Regulation Of Stem Cell Clinics
- Fed. Circ. Backs Decision Clearing Pfizer On Heart Drug IP
- Mallinckrodt Tries To Stop Another Oxide Rival
- Ex-Lab Manager Says Takeda Unit Allowed Bias, Retaliation
- 6 Ways To Avoid Compounding Errors When Practicing Law
- 4 Firms Lead Med Tech, Clean Energy SPAC Deals
- Janssen Says Whistleblower Dragging Feet In Kickback Case
- Bankruptcy Cases And Trends To Watch In 2023
- Predictions In 3 Key Areas For IP Practitioners This Year
- Illinois Cases To Watch In 2023
- Top 10 Whistleblowing And Retaliation Events of 2022
- Where Key Patent Policy Issues Stand In 2023
- 2022: The Year In Psychedelic Law And Policy
- Health Care & Life Sciences Litigation To Watch In 2023
- State AGs May Double Down On Bipartisan Issues In 2023
- Patent Cases To Watch In 2023
- Top Product Liability Cases Of 2022
- 2 States Take The Lead On Regulating Psychedelics
- Health & Life Sciences Attys Share Policy Predictions For 2023
- California Cases To Watch In 2023
- Trials To Watch In 2023
- What Will Keep Legal Talent Professionals Up At Night In 2023
- The Cybersecurity Stories That Could Define 2023
- Product Liability Cases To Watch In 2023
- Gov't Contracts Cases To Watch In 2023
- Top 4 Gov't Contracting Policies To Watch In 2023